NAF1 and cancer: The findings that NAF-1(−) cells have an even higher dependency on glycolysis (Figs 5 and 6) compared to control breast cancer cells suggest that anti-glycolytic cancer therapies might be successfully used in conjunction with therapies targeting NAF-1–BCL-2 interactions.